Drug
Albuvirtide
Albuvirtide is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
60%
Ph phase_1
1
20%
Ph phase_3
1
20%
Phase Distribution
1
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Other(3)
Detailed Status
unknown3
Completed2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)
Trials by Status
completed240%
unknown360%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
NCT05206019
completedphase_3
Test Albuvirtide in Experienced Patients
NCT02369965
unknownphase_2
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
NCT03719664
unknownphase_2
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
NCT04560569
unknownphase_2
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
NCT04819347
Clinical Trials (5)
Showing 5 of 5 trials
NCT05206019Phase 1
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
NCT02369965Phase 3
Test Albuvirtide in Experienced Patients
NCT03719664Phase 2
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
NCT04560569Phase 2
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
NCT04819347Phase 2
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5